Sales Manager, Western North America at Sino Biological, Inc._Recombinant Protein/Antibody, Active Enzymes Solutions
Last but the BEST conference before the year end 🎉🤩! Stop by our booth #411 at Antibody Engineering & Therapeutics #AET and meet with Mr. Snail/Mrs. Snail and their new friend, Coco!
For those of you who missed my presentation at AE&T or would like to see the slides again, here is my presentation: "Antibodies to Watch in 2024: mid year update and key development metrics"
We are pleased to share Silvia Crescioli's "Antibodies to Watch in 2024: mid-year update" presentation given at Antibody Engineering & Therapeutics Europe on June 4th (updated to include a sponsor's new logo). Enjoy!
The Antibody and Engineering Therapeutics Europe conference is next week! Join Stefanie Kall, Ph.D. for a talk on how to de-risk your antibody development workflows using high-resolution thermal and colloidal stability data on your antibody constructs. Stop by booth #18 to chat more about antibody stability characterization. #AntibodyEng
Grant Harradence from Abzena discusses how the use of CellTiter-Glo® Cell Viability Assay for early Antibody Drug Conjugate (ADC) candidate selection and RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay for advanced insights into bioconjugates’ mode of action, enhances both the data quality and efficiency of the ADC discovery process in this short video. You can discover more at https://bit.ly/4ixmZPA #assays #ADC biotech
“It’s a scientist’s dream to have something you worked on be approved.” – Dr. Nina E. Weisser, Director, Multispecific Antibody Therapeutics at Zymeworks. Nina shares the journey of innovation, teamwork, and dedication in the development of our recent FDA-approved therapy designed with our Azymetric™ platform. This milestone is a testament to the incredible passion and collaboration of our team as we strive to make a meaningful difference in the lives of patients with difficult-to-treat diseases.. Watch the story and join us in celebrating this milestone! #Biotech #Innovation
Missed the webinar? No problem! 🎥 Watch the playback of "Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab™ and High-Throughput Single B Cell Screening AbDrop™". 🔗 https://lnkd.in/gBtAEYWS 💡 Ready to elevate your antibody drug discovery journey? Share your thoughts and explore further insights in the comments below! #Webinar #AntibodyDrugDiscovery #HUGOAb #AbDrop #Biotech #Research #Cyagen #antibody #scienceandcommunication
Join us Feb 28 the upcoming Webinar to learn how Beacon technology enables raipd discovery of monicolonal antibodies across different species and B cell sources!!!
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery. Join us Feb 28 at to learn how researchers leverage optofluidic technology to perform upfront, in-depth functional characterization, and how the technology enables rapid discovery of high value monoclonal antibodies across many different species and B cell sources. Get the full information on our blog: https://hubs.ly/Q02lp50v0
Our understanding of antibody therapeutics continues to evolve, but the human body remains a black box. By analyzing dynamics downstream of binding, Abalytics leverages insights into how molecules interact with ligands and cells to enable advanced functions, such as trafficking, degradation, and targeted drug delivery.
After announcing the collaboration of #YUMAB and #BioCopy, first proof of concept data on TCR-like antibodies were presented on this year #FOB in Basel. These antibodies show superior target specificity and sensitivity as compared to established reference antibodies. Together, we will expand our antibody discovery pipeline to novel TCRm targets for the development of novel therapeutics with improved specificity profiles. Stay tuned for further news 😉. #BioCopy #YUMAB #TCRm #Collaboration #Antibody
Introduce more specificity, greater sensitivity and better method performance into your bioanalytical projects. Developed in collaboration with our colleagues of B2S Life Sciences, our new innovative workflow allows for preclinical quantitation of monoclonal antibodies (mAbs) and antibody drug conjugates (ADCs). Download our paper today, and let's talk about how we can help drastically increase your bioanalysis lead times. https://lnkd.in/eE_xApGv #Bioanalysis #LCMS #GLP #AntibodyDrugConjugates #MonoclonalAntibodies
